Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion
|
|
- Kerry Todd
- 6 years ago
- Views:
Transcription
1 Howard et al. Reproductive Health (27) 4:7 DOI.86/s RESEARCH Open Access Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion Brandon Howard *, ElizaBeth Grubb 2, Maureen J. Lage 3 and Boxiong Tang 4 Abstract Background: Long-acting reversible contraceptives such as intrauterine devices (IUDs) are highly effective in preventing pregnancy, cost effective, and increasing in popularity. It is unclear whether changes in IUD use are associated with changes in rates of irreversible tubal sterilization. In this analysis, we evaluate changes in rates of tubal sterilization, insertion of copper or levonorgestrel (LNG) IUDs, and related complications over time. Methods: Data were obtained from a retrospective claims database (Optum TM Clinformatics TM Data Mart) of women aged 5 to 45 years who underwent insertion of copper or or tubal sterilization between //26 and 2/3/2. Outcomes of interest included annual rates of insertion or sterilization and annual rates of potential complications and side effects. Results: The number of women included in the analysis each year ranged from,87,675 to 2,6,96. Between 26 and 2, copper IUD insertion claim rates increased from.8 to.25% and insertion claim rates increased from.63 to.5%, while sterilization claims decreased from.78 to.66% (P <. for all comparisons). Increases in IUD insertion were apparent in all age groups; decreases in tubal sterilization occurred in women aged 2 to 34 years. The most common side effects and complications were amenorrhea ( %), heavy menstrual bleeding ( %), and pelvic pain ( %). Significant increases in claims of certain complications associated with IUD insertion or sterilization were also observed. Conclusion: Between 26 and 2, a decrease in sterilization rates accompanied an increase in IUD insertion rates, suggesting that increasing numbers of women opted for reversible methods of long-term contraception over permanent sterilization. Keywords:, Levonorgestrel IUD, Tubal sterilization Plain English summary Long-acting reversible contraceptives such as intrauterine devices (IUDs) are among the most effective options for preventing pregnancy, and their popularity is increasing. However, whether changes in IUD use are associated with changes in rates of tubal sterilization, a largely irreversible and permanent contraceptive option, is unclear. In this study, we evaluated changes in rates of tubal sterilization, insertion of two different types of IUDs (copper or levonorgestrel [LNG] IUDs) and side effects associated with these devices over time. Data * Correspondence: Brandihoward@gmail.com Teva Global Medical Affairs, 4 Moores Road, Frazer, PA 9355, USA Full list of author information is available at the end of the article were obtained from an insurance claims database that included women aged 5 to 45 years who underwent insertion of copper or insertion or tubal sterilization between //26 and 2/3/2. Approximately 2 million women were included in the database each year. Between 26 and 2, copper IUD insertion rates increased from.8 to.25% and insertion rates increased from.63 to.5%, while sterilization claims decreased from.78 to.66%. Increases in IUD insertion were apparent in all age groups; decreases in tubal sterilization occurred in women aged 2 to 34 years. Results from our study suggest that increasing numbers of women are opting for copper and s over permanent sterilization. The Author(s). 27 Open Access This article is distributed under the terms of the Creative Commons Attribution 4. International License ( which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.
2 Howard et al. Reproductive Health (27) 4:7 Page 2 of 7 Background Intrauterine devices (IUDs) are the most common method of reversible contraception [, 2], used by approximately 4.3% of reproductive-aged women worldwide [3]. However, they are used only by 6.4% of American women using contraception [4]. Two commonly used IUDs in the US include the copper T38A IUD (copper IUD) and the levonorgestrel 2-mcg-releasing intrauterine device (). Both IUDs have been shown to be cost effective, have few contraindications, and are well tolerated [5 9]. Although the use of both IUDs is low in the US compared with the rest of the world, data suggest that use has substantially increased in recent years [, ]. Factors that may affect IUD use, including changes in rates of tubal sterilization, complications, or side effects have not been investigated. In this report, we compare the use and complications associated with the copper IUD,, and tubal sterilization using data obtained from the Optum Clinformatics Data Mart database. Methods The Optum Clinformatics Data Mart database is a large database of medical claims, pharmacy claims, lab results, and administrative data that contains information on patient characteristics, inpatient and outpatient encounters, and outpatient prescription drug coverage throughout the US. The database includes approximately 3 million unique individuals each year. Most individuals Table Rate of IUD insertion and tubal sterilization over time Year Total N n (%) n (%) n (%) 26,97, (.8) 2,28 (.63) 4,887 (.78) Age 5 to 9 y 293, (.2) 26 (.7) 38 (.) Age 2 to 24 y 22,95 33 (.5) 257 (.57) 45 (.2) Age 25 to 34 y 566, (.3) 623 (.) 6642 (.7) Age 35 to 45 y 827, (.6) 4325 (.52) 7756 (.94) 27,94,3 383 (.2) 6,789 (.87) 4,769 (.76) Age 5 to 9 y 299, (.3) 46 (.4) 42 (.) Age 2 to 24 y 224, (.8) 83 (.8) 444 (.2) Age 25 to 34 y 583, (.34) 8533 (.46) 647 (.) Age 35 to 45 y 832, (.6) 627 (.72) 782 (.94) 28 2,, (.22) 24,276 (.2) 4,667 (.73) Age 5 to 9 y 38,3 2 (.3) 69 (.22) 2 (.) Age 2 to 24 y 237, (.9) 2845 (.2) 4 (.7) Age 25 to 34 y 65, (.38) 2,545 (2.4) 6473 (.5) Age 35 to 45 y 84, (.8) 896 (.97) 7763 (.92) 29 2,6, (.24) 24,8 (.23) 4,88 (.74) Age 5 to 9 y 32,43 93 (.3) 777 (.25) 37 (.) Age 2 to 24 y 237, (.9) 292 (.23) 394 (.7) Age 25 to 34 y 625, (.4) 2,64 (2.2) 6232 (.) Age 35 to 45 y 84, (.2) 85 (.) 828 (.98) 2,87, (.28) 2,639 (.) 3,33 (.7) Age 5 to 9 y 289, (.5) 677 (.23) 37 (. Age 2 to 24 y 222,82 55 (.25) 2 (.94) 243 (.) Age 25 to 34 y 574, (.48),36 (.8) 5485 (.95) Age 35 to 45 y 783, (.23) 7545 (.96) 7548 (.96) 2,99, (.25) 22,35 (.5) 2,56 (.66) Age 5 to 9 y 295,377 6 (.4) 762 (.26) 24 (.) Age 2 to 24 y 265,89 6 (.23) 2648 (.) 28 (.) Age 25 to 34 y 575, (.43),694 (.86) 52 (.89) Age 35 to 45 y 772,39 54 (.2) 793 (.3) 754 (.93) P Value for Trend Over Time in the Overall Population <. <. <.
3 Howard et al. Reproductive Health (27) 4:7 Page 3 of 7 included in the database are commercially insured. The database is fully compliant with the Health Insurance Portability and Accountability Act. This study evaluated claims from January, 26, to December 3, 2, among women aged 5 45 years as of the index date, defined as the insertion date of copper IUD (Healthcare Common Procedure Coding System [HCPCS] code J73) or (HCPCS code J732), or date of sterilization by tubal ligation/tubal occlusion, based on receipt of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 66.2 or 66.3 or Current Procedure Terminology codes 586, 5865, 586, 5865, 5687, or Outcomes of interest included the rate of copper IUD insertion, insertion, and tubal sterilization by year (26 2) and by age group (ages 5 9, 2 24, 25 34, and 35 45), and changes in rate of potential complications and side effects over time. Complications and side effects were assessed based on receipt of ICD-9-CM codes for the following conditions: uterine perforation, pelvic inflammatory disease, post-insertion infection, dysmenorrhea, heavy menstrual bleeding (HMB), menorrhagia, anemia, ovarian cyst, pelvic pain, and amenorrhea. All analyses were conducted using SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA). Chi square analyses were used to analyze categorical variables; analyses of variance were used to evaluate continuous variables. Findings with associated P values <.5 were considered statistically significant. Results The number of women included in the analysis each year ranged from,87,675 to 2,6,96. Rates of tubal sterilization decreased and rates of insertion of both copper and s increased between 26 and 2 (Table, Fig. ). The percentage of women who underwent tubal ligation/tubal occlusion decreased from.78% (4,887/,97,748) in 26 to.66% (2,56/,99,36) in 2 (P <.), while rates of copper IUD insertion increased Fig. Rate of claims related to copper IUD insertion, insertion, and tubal sterilization by year of insertion/sterilization a b c d Rate in Women Aged 5 to 9 Years Rate in Women Aged 2 to 24 Years Rate in Women Aged 25 to 34 Years Rate in Women Aged 35 to 45 Years Fig. 2 Rate of claims related to copper IUD insertion, insertion, and tubal sterilization by year of insertion or sterilization in women aged 5 to 9 years (a), 2 to 24 years (b), 25 to 34 years (c),and35to45years(d)
4 Howard et al. Reproductive Health (27) 4:7 Page 4 of 7 Table 2 Complications and side effects associated with IUD insertion and tubal sterilization over time Complications/Side Effect n (%) n (%) n (%) Amenorrhea (ICD ) Total (26 2) 2385 (8.99) ab 977 (7.53) ac 75 (.67) bc (8.92) 94 (7.82) 638 (.) (.2) 278 (7.6) 64 (.93) (9.2) 873 (7.72) 7 (.59) (9.2) 845 (7.44) 658 (.4) (8.62) 58 (7.36) 429 (.73) (8.2) 622 (7.36) 37 (.92) P Value Anemia (ICD-9 28.xx) Total (26 2) 595 (2.24) b 2832 (2.35) c 23 (3.32) bc (.94) 279 (2.32) 435 (2.92) (2.5) 386 (2.3) 433 (2.93) 28 6 (2.37) 538 (2.22) 492 (3.35) 29 9 (2.44) 6 (2.42) 53 (3.45) 2 35 (2.57) 52 (2.48) 48 (3.6) 2 9 (.92) 57 (2.35) 469 (3.73) P Value Dysmenorrhea (ICD ) Total (26 2) 733 (2.76) ab 399 (3.24) ac 249 (4.2) bc 26 9 (2.6) 378 (3.4) 587 (3.94) (2.5) 566 (3.37) 59 (4.) (2.95) 723 (2.98) 598 (4.8) (2.86) 87 (3.25) 647 (4.35) 2 37 (2.6) 692 (3.35) 649 (4.87) 2 4 (2.99) 743 (3.37) 66 (4.82) P Value <. Heavy Menstrual Bleeding (ICD ) Total (26 2) 37 (5.6) ab 24 (8.46) ac 7328 (2.3) bc (5.9) 48 (8.7) 687 (.33) (5.2) 46 (8.37) 75 (.85) (5.) 846 (7.6) 922 (3.) (5.26) 992 (8.3) 245 (3.74) 2 26 (4.98) 88 (9.) 26 (5.7) (4.85) 23 (9.22) 97 (5.69) P Value.3527 <. <. Infection (ICD x) Total (26 2) 5 (.6) 88 (.7) c 8 (.3) c 26 4 (.2) 2 (.) 2 (.) 27 (.3) 4 (.8) 2 (.) 28 6 (.3) 5 (.6) 7 (.5) 29 2 (.4) 25 (.) 4 (.3) 2 (.) 4 (.7) 4 (.3)
5 Howard et al. Reproductive Health (27) 4:7 Page 5 of 7 Table 2 Complications and side effects associated with IUD insertion and tubal sterilization over time (Continued) 2 2 (.4) 8 (.4) 5 (.4) P Value Menorrhagia (ICD ) Total (26 2) 53 (.2) ab 528 (.44) ac 4 (.68) bc 26 2 (.35) 48 (.4) 88 (.59) 27 6 (.6) 58 (.35) 94 (.64) 28 (.25) 84 (.35) 92 (.63) 29 2 (.25) 89 (.36) 9 (.8) 2 8 (.5) 2 (.59) 2 (.9) 2 4 (.9) 28 (.58) 26 (.) P Value.8 <. <. Ovarian Cyst (ICD ) Total (26 2) 57 (4.36) ab 634 (5.26) ac 4324 (7.6) bc 26 4 (4.5) 539 (4.48) 45 (7.2) (4.8) 786 (4.68) 99 (6.7) 28 2 (4.72) 268 (5.22) 76 (7.34) (4.29) 4 (5.64) 39 (6.98) (4.25) 42 (5.53) 3 (7.53) 2 29 (4.68) 25 (5.47) 9 (7.25) P Value.597 <..975 Pelvic Inflammatory Disease (ICD-9 64.xx 66.xx) Total (26 2) 553 (9.5) ab 9 63 (5.8) ac 62 (8.48) bc 26 3 (.38) 4 (.33) 64 (.43) 27 2 (.32) 53 (.32) 66 (.45) (.5) 74 (.3) 69 (.47) 29 5 (.3) 6 (.24) 54 (.37) 2 2 (.23) 49 (.24) 4 (.3) 2 8 (.38) 58 (.26) 25 (.2) P Value Pelvic Pain (ICD , 789.) Total (26 2) 3222 (2.5) ab 3 89 (.52) ac 8323 (3.78) bc (.2) 395 (.6) 987 (3.35) (2.25) 95 (.4) 997 (3.52) (.6) 2729 (.24) 976 (3.47) (2.88) 2897 (.68) 27 (4.23) 2 66 (2.6) 249 (.72) 88 (4.3) (2.7) 2536 (.5) 792 (4.27) P Value Perforation of Uterine Wall (ICD , 665.3) Total (26 2) 42 (.55) ab 558 (.29) ac 387 (.64) bc 26 4 (.6) 42 (.8) 57 (.38) 27 5 (.34) 76 (.5) 76 (.5) (.7) 3 (.24) 9 (.62) (.8) 39 (.29) 9 (.8)
6 Howard et al. Reproductive Health (27) 4:7 Page 6 of 7 Table 2 Complications and side effects associated with IUD insertion and tubal sterilization over time (Continued) 2 98 (.87) 37 (.49) 3 (.77) 2 87 (.86) 33 (.42) 9 (.87) P Value.4.23 <. abc Chi square pairwise comparisons between groups with the same superscript, P <.5. The pairwise comparisons were done for the total for each complication/ side effect across years 26 2 and not for the individual years from.8% (3,454/,97,748) to.25% (4,682/,99,36) (P <.) and rates of insertion increased from.63% (2,28/,97,748) to.5% (22,35/,99,36) (P <.) from 26 to 2, respectively. Increases in IUD insertion and decreases in tubal sterilization rates were apparent in most age groups (Table, Fig. 2). The greatest decreases in rates of sterilization occurred in women ages Although insertion of either IUD in adolescents ages 5 9 was rare, the copper IUD insertion rate doubled and the insertion rate more than tripled in this age group between 26 and 2. Rates of complications or side effects were low and are shown in Table 2. The most common side effects and complications were amenorrhea ( %), HMB ( %), and pelvic pain ( %). Significant increases over time were observed in rates of perforation of the uterine wall in all groups, HMB and menorrhagia with and tubal sterilization, dysmenorrhea and anemia with sterilization, and ovarian cysts with. A significant decrease in pelvic inflammatory disease was observed over time among women who underwent sterilization. Discussion Results indicate that tubal sterilization rates decreased and IUD insertion rates increased between 26 and 2. These findings were noted across all age groups, with the exception of sterilization in women ages 35 45, the rates of which were constant. By 28, insertion rates of exceeded rates of sterilization in every age group, including women ages Importantly, substantial increases in insertion rates for both the copper and s were seen in younger women, including adolescents. Results suggesting an increase in IUD use are consistent with data from the National Survey of Family Growth, which showed that from 22 to 23, the prevalence of IUD use increased from 2. to.3% among female contraceptive users aged 5 44 years [2]. The prevalence of female sterilization in the same population decreased from 27. to 25.% over the same time period. In a separate analysis of sexually active women aged 5 24 years, IUD use increased from.2 to 2.5% in teens ages 5 9 and from 2. to 5.4% in women aged 2 24 years, although the increase was primarily observed in parous women []. Another retrospective cohort study found that IUD insertion rates increased nearly 7-fold between 22 and 29 [6]. Importantly, women experienced few complications with either IUD. Differences in complication rates between IUDs were of minimal clinical significance. The most frequent complications in both IUD groups were menstrual disorders and pelvic pain; however, patients who underwent tubal sterilization reported these adverse effects more frequently than IUD users. The most serious complications associated with IUD use, such as uterine perforation and pelvic inflammatory disease, were reported in fewer than 2% of women. Limitations of the study included its observational, retrospective nature, lack of representation of women without health insurance, and nature of claims databases. Despite these limitations, our findings confirm recent data suggesting a shift toward long-acting reversible contraceptive methods and away from permanent methods. Copper IUD and insertion and tubal sterilization were associated with a low rate of complications. Conclusions Our analysis of a retrospective claims database supported an increase in women selecting reversible methods of longterm contraception over permanent tubal sterilization, as shownbyanincreaseincopperiudandlngiudinsertion rates and decreased sterilization rates between 26 and 2. Younger women showed substantial increases in IUD insertion rates. Among all women, rates of complications or side effects were low. Abbreviations HCPCS: Healthcare Common Procedure Coding System; HMB: Heavy menstrual bleeding; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification; IUD: Intrauterine device; LNG: Levonorgestrel Acknowledgement The authors thank Nicole Cooper of MedVal Scientific Information Services, LLC, for providing medical writing and editorial assistance. This manuscript was prepared according to the International Society for Medical Publication Professionals Good Publication Practice for Communicating Company- Sponsored Medical Research: the GPP2 Guidelines and the International Committee of Medical Journal Editors Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Funding This analysis was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. Medical writing assistance was provided by MedVal Scientific Information Services, LLC (Skillman, NJ), and was funded by Teva Branded Pharmaceutical Products R&D, Inc. (Frazer, PA). Teva provided a full review of the article.
7 Howard et al. Reproductive Health (27) 4:7 Page 7 of 7 Availability of data and materials The datasets generated during and/or analyzed during the current study are available in the Optum Clinformatics Data Mart database. Authors contributions Study concept and design: BH, EG, ML, BT. Acquisition, analysis, or interpretation of data: All authors. Drafting of manuscript: All authors. Critical revisions of manuscript for important intellectual content: All authors. Statistical analysis: ML. Final approval of manuscript: All authors.. Whitaker AK, Sisco KM, Tomlinson AN, Dude AM, Martins SL. Use of the intrauterine device among adolescent and young adult women in the United States from 22 to 2. J Adolesc Health. 23;53: Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 5 44: United States, Natl Health Stat Report. 25;86: 4. Competing interests Brandon Howard was an employee of Teva Global Medical Affairs at the time this work was conducted; ElizaBeth Grubb was an employee of Teva Global Health Economics & Outcomes Research at the time this work was conducted; Maureen J. Lage is the managing member of HealthMetrics Outcomes Research and was compensated by Teva Branded Pharmaceutical Products, R&D, Inc. for her work on this project. Boxiong Tang is an employee of Teva Global Health Economics & Outcomes Research. Consent for publication Not applicable. Ethics approval and consent to participate Not applicable. Publisher s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Author details Teva Global Medical Affairs, 4 Moores Road, Frazer, PA 9355, USA. 2 Teva Global Health Economics & Outcomes Research, Nall Ave, Overland Park, KS 662, USA. 3 HealthMetrics Outcomes Research, River Reach Dr., Bonita Springs, FL 3434, USA. 4 Teva Global Health Economics & Outcomes Research, 4 Moores Road, Frazer, PA 9355, USA. Received: 24 August 26 Accepted: 3 May 27 References. D Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 27;75(6 suppl):s Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine copper T-38A contraceptive device. Int J Women s Health. 2;2: Buhling KJ, Zite NB, Lotke P, Black K. Worldwide use of intrauterine contraception: a review. Contraception. 24;89: Branum A, Jones J. Trends in long-acting reversible contraception use among U.S. women aged NCHS Data Brief. 25;88: National Center for Chronic Disease Prevention and Health Promotion. U.S. selected practice recommendations for contraceptive use, 23: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. Morb Mortal Wkly Rep. 23;62: Berenson AB, Tan A, Hirth JM, Wilkinson GS. Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol. 23;2: Foster DG, Rostovtseva DP, Brindis CD, Biggs MA, Hulett D, Darney PD. Cost savings from the provision of specific methods of contraception in a publicly funded program. Am J Public Health. 29;99: Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception. 23; 87: Trussell J, Hassan F, Lowin J, Law A, Filonenko A. Achieving cost-neutrality with long-acting reversible contraceptive methods. Contraception. 25;9: Xu X, Macaluso M, Ouyang L, Kulczycki A, Grosse SD. Revival of the intrauterine device: increased insertions among US women with employersponsored insurance, Contraception. 22;85:55 9. Submit your next manuscript to BioMed Central and we will help you at every step: We accept pre-submission inquiries Our selector tool helps you to find the most relevant journal We provide round the clock customer support Convenient online submission Thorough peer review Inclusion in PubMed and all major indexing services Maximum visibility for your research Submit your manuscript at
Patient Awareness and Understanding of Intrauterine Devices
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Patient Awareness and Understanding of Intrauterine Devices Lindsey Marie Eastman University
More informationAccording to data from the 2006 to 2008 National Survey
ORIGINAL RESEARCH Modeled Cost Differences Associated With Use of Levonorgestrel Intrauterine Devices Amy Law, PharmD; Mark McCoy, PharmD, MBA; Melissa Lingohr-Smith, PhD; Jay Lin, PhD, MBA; and Richard
More informationThe Pennsylvania State University. The Graduate School. Department of Public Health Sciences
The Pennsylvania State University The Graduate School Department of Public Health Sciences THE IMPACT OF THE AFFORDABLE CARE ACT ON CONTRACEPTIVE USE AND COSTS AMONG PRIVATELY INSURED WOMEN A Thesis in
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More informationUpper extremity open fractures in hospitalized road traffic accident patients: adult versus pediatric cases
Rubin et al. Journal of Orthopaedic Surgery and Research (2017) 12:157 DOI 10.1186/s13018-017-0657-1 RESEARCH ARTICLE Open Access Upper extremity in hospitalized road traffic accident : adult versus pediatric
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationLARC IN THE OFFICE BASE SETTING. Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine
SHIFT HAPPENS! LARC IN THE OFFICE BASE SETTING Regina Lewis, DO Associate Professor of Family Medicine OSU Family Medicine 1. the effects of teen and unplanned pregnancies 2. types of LARC products 3.
More informationIntrauterine Devices (IUDs): Access for Women in the U.S.
November 2016 Fact Sheet Intrauterine Devices (IUDs): Access for Women in the U.S. Intrauterine devices (IUDs) are one of the most effective forms of reversible contraception. IUDs, along with implants,
More informationPublications on Family PACT
Publications on Family PACT 2015 The impact of postpartum contraception on reducing preterm birth: Findings from California. Rodriguez M, Chang R, Thiel de Bocanegra H. American Journal of Obstetrics &
More informationFamily Planning Eligibility Program
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2
More informationTakashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6
Yagisawa et al. Renal Replacement Therapy (2016) 2:68 DOI 10.1186/s41100-016-0080-9 POSITION STATEMENT Current status of kidney transplantation in Japan in 2015: the data of the Kidney Transplant Registry
More informationLONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables
LONG-ACTING REVERSIBLE CONTRACEPTION Summary Tables Bridging the Divide: A Project of the Jacobs Institute of Women s Health June 2016 Table 1. Summary of LARC Methods Available Years Since Effective Copper
More informationIntrauterine Devices and Pelvic Inflammatory Disease: Dispelling the Myth. Dr Amy Moten SHine SA Co-authors: Dr Richelle Douglas; Dr Alison Creagh SHQ
Australasian Sexual Health Conference Adelaide, November 14-16 Intrauterine Devices and Pelvic Inflammatory Disease: Dispelling the Myth Dr Amy Moten SHine SA Co-authors: Dr Richelle Douglas; Dr Alison
More informationCoding for the Contraceptive Implant and IUDs
LARC Quick Coding Guide 2018 UPDATE Coding for the Contraceptive Implant and IUDs CORRECT CODING can result in more appropriate compensation for services and devices. To help practices receive appropriate
More informationDoes serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study
Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian
More informationUnintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use
3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationThe most commonly chosen methods of contraception
Original Research Effects of Age, Parity, and Device Type on Complications and Discontinuation of Intrauterine Devices Joelle Aoun, MD, Virginia A. Dines, BS, Dale W. Stovall, MD, Mihriye Mete, PhD, Casey
More informationTorsion bottle, a very simple, reliable, and cheap tool for a basic scoliosis screening
Romano and Mastrantonio Scoliosis and Spinal Disorders (2018) 13:4 DOI 10.1186/s13013-018-0150-6 RESEARCH Open Access Torsion bottle, a very simple, reliable, and cheap tool for a basic scoliosis screening
More informationLEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common
4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationEffectiveness of the surgical torque limiter: a model comparing drill- and hand-based screw insertion into locking plates
Ioannou et al. Journal of Orthopaedic Surgery and Research (2016) 11:118 DOI 10.1186/s13018-016-0458-y RESEARCH ARTICLE Effectiveness of the surgical torque limiter: a model comparing drill- and hand-based
More informationCT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series
Malalagama et al. Cancer Imaging (2017) 17:17 DOI 10.1186/s40644-017-0119-3 CASE SERIES CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series Geethal N. Malalagama
More informationCODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40
CODING GUIDELINES FOR CONTRACEPTIVES Effective June 1, 2017 Version 1.40 TABLE OF CONTENTS ICD-10 CM Diagnosis Codes: Encounter for Contraception page 2 Coding for IUD Insertion and Removal Procedures
More informationBRIEF REPORTS. Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH
Providing Long-Acting Reversible Contraception in an Academic Family Medicine Center Jennifer Amico, MD, MPH; Justine Wu, MD, MPH BACKGROUND AND OBJECTIVES: Providing long-acting reversible contraception
More informationESSURE A RESOURCE FOR CODING
ESSURE REIMBURSEMENT GUIDE A RESOURCE FOR CODING INDICATION Essure is indicated for women who desire permanent birth control (female sterilization) by bilateral occlusion of fallopian tubes. IMPORTANT
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More informationProduct Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More informationA hemodialysis cohort study of protocolbased anticoagulation management
DOI 10.1186/s13104-017-2381-7 BMC Research Notes RESEARCH ARTICLE A hemodialysis cohort study of protocolbased anticoagulation management S. Lamontagne 1,2*, Tinzar Basein 3, Binyue Chang 3 and Lakshmi
More informationContraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014
Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationBLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018
BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What
More informationContraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016
Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016 Disclosure I am a Nexplanon trainer for Merck. Objectives Understand how obesity may affect pharmacokinetics
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationMEDICAL POLICY SUBJECT: FEMALE STERILIZATION. POLICY NUMBER: CATEGORY: Contract Clarification
MEDICAL POLICY SUBJECT: FEMALE STERILIZATION PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationMaximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community
Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community Reproductive Health 2012 September 21, 2012 David Turok, MD/MPH Objectives Communicate to colleagues the reduction
More informationWendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa
Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates
More informationPer Capita Health Care Spending on Diabetes:
Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes
More informationRelationship between incident types and impact on patients in drug name errors: a correlational study
Tsuji et al. Journal of Pharmaceutical Health Care and Sciences (2015) 1:11 DOI 10.1186/s40780-015-0011-x RESEARCH ARTICLE Open Access Relationship between incident types and impact on patients in drug
More informationTranscervical Sterilization
Q UESTIONS & ANSWERS A BOUT Transcervical Sterilization A New Choice in Permanent Birth Control Choosing a Birth Control Method Women and their partners now have more birth control choices than ever. How
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationCost-benefit analysis of state and hospital funded postpartum intrauterine contraception for recent immigrants to the United States
2010 Contraception Outstanding Article September 23, 2010 Cost-benefit analysis of state and hospital funded postpartum intrauterine contraception for recent immigrants to the United States Maria Rodriguez,
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationContraception and gynecological pathologies
1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about
More informationRESOLUTION NO. 301 (Co-Sponsored G) SUBSTITUTE ADOPTED See Below
RESOLUTION NO. 301 (Co-Sponsored G) SUBSTITUTE ADOPTED See Below Support Placement and Coverage of Long-Acting Reversible Contraceptives (LARC) in the Early Postpartum Period Introduced by the California
More informationAssessment of knowledge and education relating to asthma during pregnancy among women of childbearing age
Al Ghobain et al. Asthma Research and Practice (2018) 4:2 DOI 10.1186/s40733-017-0038-x RESEARCH Open Access Assessment of knowledge and education relating to asthma during pregnancy among women of childbearing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationAn Overview of Long Acting Reversible Contraception Methods
An Overview of Long Acting Reversible Contraception Methods Unintended Pregnancy All pregnancies should be intended; that is, they should be consciously and clearly desired at the time of conception. -
More informationClinical Policy: Essure Removal Reference Number: CP.MP.131
Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationThe number of women using long-acting reversible
Long-acting reversible contraception: Who, what, when, and how This review provides practical tips and dispels some common misconceptions about these devices, which have higher rates of patient satisfaction
More informationEmergency Contraception THE FACTS
Emergency Contraception Quick Facts What is it? Emergency contraception is birth control that you use after you have had unprotected sex--if you didn t use birth control or your regular birth control failed.
More informationUnilateral lateral rectus muscle advancement surgery based on one-fourth of the angle of consecutive esotropia
Kim and Lee BMC Ophthalmology (2017) 17:266 DOI 10.1186/s12886-017-0658-1 RESEARCH ARTICLE Open Access Unilateral lateral rectus muscle advancement surgery based on one-fourth of the angle of consecutive
More informationConference presentation to publication: a retrospective study evaluating quality of abstracts and journal articles in medical education research
Stephenson et al. BMC Medical Education (2017) 17:193 DOI 10.1186/s12909-017-1048-3 RESEARCH ARTICLE Conference presentation to publication: a retrospective study evaluating quality of abstracts and journal
More informationA systematic review of some of the side effects of copper T380 intrauterine contraceptive device
A systematic review of some of the side effects of copper T380 intrauterine contraceptive device Ahmed Nehad Ahmed Hatem Askalani IAMANEH Scholarship Reproductive Health Research Course Geneva, 2006 Introduction
More informationHospital Discharge Data
Hospital Discharge Data West Virginia Health Care Authority Hospitalization data were obtained from the West Virginia Health Care Authority s (WVHCA) hospital discharge database. Data are submitted by
More informationThe Impact of Title X on Publicly Funded Family Planning Services in California: Access and Quality
The Impact of Title X on Publicly Funded Family Planning Services in California: Access and Quality J A N U A RY 2 0 1 4 The Impact of Title X on Publicly Funded Family Planning Services in California:
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationFACT SHEET: Copper IUD
FACT SHEET: Copper IUD How does the copper IUD help me? The copper IUD is a hormone-free option. If you don t like the copper IUD or you decide to get pregnant, your health care provider can remove the
More informationContraception. IUC s, Sterilization
Contraception IUC s, Sterilization Intrauterine Contraceptives (IUC s) IUC s are made of flexible plas4c, available only through prescrip4on Three types ParaGard (copper) Mirena (hormone) Skyla (hormone)
More informationTreatment patterns for women with new episodes of uterine myomas in an insured population in the US
Current Medical Research and Opinion Vol. 22, No. 1, 2006, 95 100 2006 LibraPharm Limited 0300-7995 doi:10.1185/030079906x80323 All rights reserved: reproduction in whole or part not permitted ORIGINAL
More informationNIH Public Access Author Manuscript Perspect Sex Reprod Health. Author manuscript; available in PMC 2012 September 01.
NIH Public Access Author Manuscript Published in final edited form as: Perspect Sex Reprod Health. 2011 September ; 43(3): 181 187. doi:10.1363/4318111. Race, Ethnicity and Differences in Contraception
More informationDay of Learning: Current Best Practices for Contraceptive Provision
Day of Learning: Current Best Practices for Contraceptive Provision Thank you to our Sponsors Carnegie Science Center Jewish Healthcare Foundation Allegheny Health Network s Center for Inclusion Health
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.HNMC.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationExtended use of intrauterine devices: How long can we go?
Extended use of intrauterine devices: How long can we go? Justine P. Wu, MD, MPH Sarah Pickle, MD Rutgers Robert Wood Johnson Medical School Department of Family Medicine & Community Health Disclosures
More informationLigation of lymph vessels for the treatment of recurrent inguinal lymphoceles following lymphadenectomy
Syddansk Universitet Ligation of lymph vessels for the treatment of recurrent inguinal lymphoceles following lymphadenectomy Toyserkani, Navid Mohamadpour; Nielsen, Henrik Toft; Bakholdt, Vivi T.; Sørensen,
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationContraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE
Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)
More informationPregabalin prescription for terminally ill cancer patients receiving specialist palliative care in an acute hospital
Yajima et al. Journal of Pharmaceutical Health Care and Sciences (2016) 2:29 DOI 10.1186/s40780-016-0063-6 RESEARCH ARTICLE Open Access Pregabalin prescription for terminally ill cancer patients receiving
More informationPrescriber and Pharmacy Guide for the Tracleer REMS Program
Prescriber and Pharmacy Guide for the Tracleer REMS Program Please see accompanying full Prescribing Information, including BOXED WARNING for hepatotoxicity and teratogenicity. Introduction to Tracleer
More informationMedical Eligibility for Contraception Use
Medical Eligibility for Contraception Use DIVISION OF REPRODUCTIVE HEALTH CENTERS FOR DISEASE CONTROL AND PREVENTION 2016 US Medical Eligibility Criteria for Contraceptive Use (US MEC) Purpose To assist
More informationالحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم..
الحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم.. سيدنا 11/6/2013 1 Goals of Family Planning services : 1- Enable women and
More informationLong Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG
Long Acting Reversible Contraception: First Line Care for Adolescents David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG Disclosures Melissa Kottke is a Nexplanon trainer for Merck Objectives Describe
More informationThe Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH
The Doctor Is In Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH Contraception Resources from the CDC: 2016 U.S. Medical Eligibility Criteria
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing
More informationLong-Acting Reversible Contraception: The Contraceptive CHOICE Project
Long-Acting Reversible Contraception: The Contraceptive CHOICE Project Jeffrey F. Peipert, M.D., Ph.D. Vice Chair of Clinical Research Robert J. Terry Professor Department of Obstetrics & Gynecology Washington
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationCONTRACEPTION OLD FRIENDS, NEW TRENDS
CONTRACEPTION OLD FRIENDS, NEW TRENDS AAP RECOMMENDATIONS 2014 1. Council about and ensure access to all contraceptive methods safe and appropriate describing most effective first. PEDIATRICS 134 (4)
More informationHormonal Contraception: Asian View. Hormonal Contraception: Asian View: focused on Chinese View. Prof.Dr.Xiangyan Ruan, MD.PhD
Asian View Prof.Dr.Xiangyan Ruan, MD.PhD Beijing Obstetrics & Gynecology Hospital, Capital Medical University (China) WHO Collaborative Centre - Director of Dept. of Gynecological Endocrinology & & - Fertility
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Transmucosal Immediate Release Fentanyl Products Reference Number: CP.CPA.211 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2013 Publication date 24 September 2013 A National Statistics Publication for Scotland
More informationOur Moment of Truth 2013 Survey Women s Health Care Experiences & Perceptions: Spotlight on Family Planning & Contraception
Our Moment of Truth 2013 Survey Women s Health Care Experiences & Perceptions: Spotlight on Family Planning & Contraception Thank you for taking part in this survey. We know your time is valuable. Through
More informationNotes to Teacher continued Contraceptive Considerations
Abstinence a conscious decision to refrain from sexual intercourse 100% pregnancy will not occur if close contact between the penis and vagina does not take place. The risk of a number of STDs, including
More informationPermanent Sterilisation to Long-Acting Reversible Contraception: Is a Paradigm Shift Necessary?
DOI 10.1007/s13224-016-0866-2 INVITED MINI REVIEW Permanent Sterilisation to Long-Acting Reversible Contraception: Is a Paradigm Shift Necessary? S. Shantha Kumari 1 Received: 28 September 2015 / Accepted:
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2014 Publication date 30 September 2014 A National Statistics Publication for Scotland
More informationContraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital
Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception
More informationDownloaded from:
Ellingjord-Dale, M; Vos, L; Tretli, S; Hofvind, S; Dos-Santos-Silva, I; Ursin, G (2017) Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening
More informationDQA Measure Technical Specifications: Administrative Claims-Based Measures Treatment Services, Dental Services
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Treatment Services, Dental Services Description:
More informationDQA Measure Technical Specifications: Administrative Claims-Based Measures Preventive Services for Children at Elevated Caries Risk, Dental Services
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Preventive Services for Children at Elevated Caries
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin ) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 8.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationKey words: Contraception, Copper T380A, Discontinuation.
Discontinuation Rates among Women Using either the Combined Oral Contraceptive Pills or an Intrauterine Contraceptive Device for Contraception: A Comparative Study Ehab Al-Rayyan MD*, Zakarya Bani Meri
More informationSimplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok
Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationWelcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.
Mirena is the #1 prescribed IUD * in the U.S. Welcome to Mirena The Mirena Handbook: A Personal Guide to Your New Mirena *Intrauterine Device Supported by 2015-2016 SHS data INDICATIONS FOR MIRENA Mirena
More information